A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
NCT ID: NCT05135975
Last Updated: 2025-08-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
86 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-07-20
Study Completion Date
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted.
The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors with minimal disease burden, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors and thereby significantly extend the period of disease control and/or induce a durable cure.
The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors with minimal disease burden, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors and thereby significantly extend the period of disease control and/or induce a durable cure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
NCT03611595
Solid Tumor
RECRUITING
PHASE1
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
NCT06156410
Ewing Sarcoma
Osteosarcoma
Sarcomas
RECRUITING
PHASE1
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
NCT02756845
Advanced Non CNS Tumors
COMPLETED
PHASE1
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
NCT01709435
Recurrent Malignant Solid Neoplasm
Recurrent Melanoma
Recurrent Primary Central Nervous System Neoplasm
+4 more
COMPLETED
PHASE1
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
NCT03458728
Relapsed or Refractory Solid Tumors or Lymphoma in Children
Neuroblastoma
Osteosarcoma
+2 more
TERMINATED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors who have achieved and maintained (for at least 4 weeks) a "best response" to their most recent line of therapy, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors, improve one-year progression-free survival by 20% as compared to historical controls, and also improve longer-term progression-free and overall survival without significant impact on quality of life. We also hypothesize, in an exploratory aim, that there will be improvement in two-year progression free survival in patients with metastatic Ewing sarcoma and osteosarcoma specifically.
The study proposes to evaluate the efficacy of up to one year of treatment with cabozantinib in pediatric solid tumors after completion of last therapy with a "best response." There are multiple reasons for this approach, as opposed to continual therapy until toxicity or disease progression alone. First, for most of these ultra-high-risk diseases, the greatest risk of recurrence has historically been within 12 months after last therapy, and often times considerably sooner. As such, we should be able to evaluate a meaningful difference within 12 months. Second, the goal of this study is to evaluate if, during a critical period of disease control, use of cabozantinib can induce a durable remission. There are active Phase 2 and 3 studies of cabozantinib, including with the Children's Oncology Group, evaluating the efficacy of cabozantinib in controlling pediatric cancers with measurable burden of disease. However, we know that, in patients with "ultra-high-risk" disease who have achieved a best response including stable disease, partial response or even complete response, there is still active disease with high risk of growth, as demonstrated in the studies cited above. Our study seeks to augment ongoing work in pediatric cancers by testing the hypothesis that cabozantinib can durably silence cancer cell viability after a best response to prior treatment. Third, this work would mark a fundamental change in the indication for use of cabozantinib in pediatric cancers, broadening its utility from a "rescue" agent to a maintenance therapy that may be critical for disease control, during either primary or secondary remission.
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted.
The study proposes to evaluate the efficacy of up to one year of treatment with cabozantinib in pediatric solid tumors after completion of last therapy with a "best response." There are multiple reasons for this approach, as opposed to continual therapy until toxicity or disease progression alone. First, for most of these ultra-high-risk diseases, the greatest risk of recurrence has historically been within 12 months after last therapy, and often times considerably sooner. As such, we should be able to evaluate a meaningful difference within 12 months. Second, the goal of this study is to evaluate if, during a critical period of disease control, use of cabozantinib can induce a durable remission. There are active Phase 2 and 3 studies of cabozantinib, including with the Children's Oncology Group, evaluating the efficacy of cabozantinib in controlling pediatric cancers with measurable burden of disease. However, we know that, in patients with "ultra-high-risk" disease who have achieved a best response including stable disease, partial response or even complete response, there is still active disease with high risk of growth, as demonstrated in the studies cited above. Our study seeks to augment ongoing work in pediatric cancers by testing the hypothesis that cabozantinib can durably silence cancer cell viability after a best response to prior treatment. Third, this work would mark a fundamental change in the indication for use of cabozantinib in pediatric cancers, broadening its utility from a "rescue" agent to a maintenance therapy that may be critical for disease control, during either primary or secondary remission.
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neuroblastoma
Sarcoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cabozantinib
Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day, to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
Group Type
EXPERIMENTAL
Cabozantinib
Intervention Type
DRUG
Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cabozantinib
Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Patients previously with measurable disease, at start of most recent line of therapy, AND without evaluable disease (or for whom assessment of potential evaluable-only disease would not be considered standard of care) are eligible based on "measurable disease response" only in Section 3.1.2.a.i.
2. Patients previously with evaluable disease at start of most recent line of therapy, AND without measurable disease at that time are eligible based on "evaluable disease" definition alone only in Section 3.1.2.a.ii.
3. Patients previously with measurable AND evaluable disease at start of most recent line of therapy must meet BOTH "measurable disease" and "evaluable disease" definitions under Section 3.1.2.a.
3.2.2. Disease Strata. Patients need to meet any single definition of disease below:
1. Stratum A: Solid tumors with 1-year PFS ≤25% (target enrollment 36 patients)
1. Neuroblastoma BR1 at the end of frontline therapy with residual disease (less than complete response (CR), including MIBG-avid stable disease as per Section 3.1.2.a.ii,.or \>5% bone marrow involvement) but not progressive at time of enrollment
2. Neuroblastoma BR2 or later.
3. Osteosarcoma, BR2 or later
4. Ewing sarcoma, BR2 or later
5. Rhabdomyosarcoma, with positive surgical margins OR with primary extremity tumor with \>2 metastases at diagnosis, BR1 or later
6. Rhabdomyosarcoma, alveolar subtype or fusion-positive subtype, BR2 or later
7. Rhabdomyosarcoma, embryonal subtype, Group 4 at original diagnosis, BR2 or later
8. Desmoplastic small round blue cell tumor, BR2 or later
9. Any other soft tissue sarcoma, BR2 or later
10. Wilms tumor, diffuse anaplasia histology, any stage, BR2 or later
11. Wilms tumor, any histology with relapse within 12 months of diagnosis, who have received prior treatment with doxorubicin, and intraabdominal recurrence, BR2 or later
12. Wilms tumor, BR3 or later
13. Other solid tumor with 1-year PFS ≤ 20% can be discussed with study chair for eligibility
2. Stratum B: Metastatic Ewing sarcoma with metastases not undergoing complete metastatectomy, BR1 (target enrollment 20 patients)
3. Stratum C: Metastatic osteosarcoma after frontline therapy, BR1 (target enrollment 20 patients)
4. Stratum D: Metastatic fusion-positive rhabdomyosarcoma after frontline therapy, BR1 (target enrollment 10 patients)
1. Age: ≥ 18 months of age and \<40 years of age at time of study enrollment
2. Performance level: Patients must have a Lansky or Karnofsky performance status score of ≥ 50, corresponding to ECOG categories 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are upright in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. Patients should also have recovery to baseline or ≤ Grade 1 CTCAE v4.03 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy (see Section 3.2.3, criteria 4)
3. Patient Body Surface Area (BSA): Patients must be ≥0.35 m2 in BSA, using the Mosteller formula, BSA = (((Height in cm) \* (Weight in kg))/ 3600)½ within two weeks of study enrollment
4. Prior therapy: patients must have recovered from the acute toxic effects of prior therapy, with the following time specifications:
1. Myelosuppressive chemotherapy: Patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment on study (6 weeks if prior therapy included nitrosourea)
2. Other medicinal anti-cancer agents: Patients must not have received non-myelosuppressive anticancer agents, including any type of small molecule kinase inhibitor, within 14 days of enrollment on study
3. Biological anticancer therapy (including antibody therapy or cellular therapy): Patients must not have received biological anticancer therapy within 21 days of enrollment on study
4. Radiation therapy: Patients must not have received external beam radiation therapy to sites outside of the lungs within 2 weeks of study enrollment, external beam radiation therapy to sites within the lungs within 4 weeks of study enrollment, or I-131 MIBG therapy within 6 weeks of study enrollment. Subjects with clinically relevant ongoing complications from prior radiation therapy MUST be discussed with Study Chair or his proxy to determine suitability and safety of enrollment.
5. Myeloablative therapy: Patients must not have received myeloablative therapy within 2 months of study enrollment, must not have received a blood stem cell/marrow infusion within 3 weeks of study enrollment, and must have attained blood count recovery as per Section 3.2.3, criteria 5
5. Bone Marrow Function: Patients must have adequate bone marrow function at time of study enrollment, as defined as:
1. Absolute neutrophil count (ANC) ≥1000/mcL; patients cannot have received filgrastim, pegfilgrastim or equivalent biosimilar within 14 days of study enrollment
2. Platelet count ≥ 100,000/mcL; patients can receive no more than 15 mL/kg of platelet transfusions per week at time of enrollment to meet the parameters; patients can receive a TPO agonist (e.g., eltrombopag or romiplostim) at time of enrollment but must be on a stable dose for at least 14 days prior to enrollment
3. Hemoglobin ≥ 8.0 g/dL; patients can receive no more than 10 mL/kg of packed red blood cells (PRBCs)/week transfused at time of enrollment on therapy to meet the parameters; patients may receive erythropoietin or biosimilar equivalent but must have been on a stable dose and not require PRBC transfusions for at least 14 days prior to study enrollment
4. Patients with residual bone marrow metastases at end of most recent line of therapy must have stable disease or better at two bone marrow evaluations at least 4 weeks apart, with the second marrow assessment at least 4 weeks after end of most recent therapy. Stable disease is defined as \<2-fold change in marrow burden between the two timepoints and ≤20% marrow involvement. When bilateral bone marrow assessment is performed, average marrow involvement of the two sites will be used for eligibility.
6. Renal Function: Patient must meet criteria for both a. and b. below to have adequate renal function, within 2 weeks of study enrollment
1. Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2, as per institutional standard testing OR serum creatinine based on age/gender as listed in protocol:
2. Urine protein: ≤ 30 mg/dl in urinalysis (clean catch recommended), equivalent to ≤ 1+ on dipstick OR quantitative urine protein \< 1000 mg in a 24hr urine sample. NOTE: If the initial urinalysis shows \>30 mg/dL urine protein (or \> 1+ on dipstick), a 24-hour quantitative urine protein should be utilized, as described above, for eligibility consideration.
7. Hepatic function: Patient must meet ALL of the below criteria, within 14 days of study enrollment, to have adequate hepatic function:
1. Total bilirubin \< 2x institutional upper limit of normal (ULN) for age
2. ALT\<5x ULN
3. Serum albumin \>2.7 g/dL
8. Cardiovascular Function: Patients must have adequate cardiovascular function as defined as:
1. No significant arrhythmias, strokes, transient ischemic attacks, or myocardial infarction within 6 months of study enrollment
2. QTc ≤ 480 msec within 7 days of study enrollment (calculated using Bazett calculation or Fridericia calculation as per institutional standard of care; whichever calculation is used for eligibility must be used for all future QTc calculations).
A single ECG with QTc meeting the above criterion is adequate. However, if an initial ECG shows a QTc \>480 ms, obtain two additional ECGs with each ECG at least 30 minutes apart. Calculate each individual QTc by the same calculation method and average the values; the resulting average QTc will be used for eligibility.
3. Blood pressure ≤ 95th percentile for age, height, and gender for patients \<18 years of age (78), or BP ≤140/90 for patients ≥18 years of age. At time of enrollment, patients may be on one antihypertensive agent at a stable dose for at least 2 weeks prior to enrollment.
9. Pancreatic function: Patient must have adequate pancreatic function, as defined by a serum lipase \<2x ULN
10. Neurologic function: Patients with defined seizures who are on a stable anti- convulsant regimen using drugs that do not induce hepatic metabolizing enzymes for at least 4 weeks are eligible for enrollment Recommended Non-enzyme inducing anticonvulsants Clonazepam Diazepam Ethosuximide Ezogabine Gabapentin Lacosamide Lamotrigine Levetiracetam Lorazepam Perampanel Tiagabine Topiramate Valproic Acid Zonisamide Unacceptable Enzyme inducing anticonvulsants Carbamazepine Felbamate Phenobarbital Fosphenytoin Phenytoin Primidone Oxcarbazepine
11. Lung integrity: Patients must not have had any invasive pulmonary procedure (including bronchoalveolar lavage, lung biopsy, transbronchial biopsy, or thoracotomy) or pneumothorax within 4 weeks of enrollment on study.
12. Surgeries or trauma:
1. Patients must not have had any major surgical procedures, laparoscopic procedures, sepsis, shock, or physical trauma requiring hospitalization within 4 weeks of enrollment on study. The primary surgeon of any major surgical procedures must authorize antineoplastic treatment before enrollment on study.
2. Patients must not have had a central line or subcutaneous port placement, revision, or removal (excluding a peripherally inserted central catheter (PICC)) within 7 days of study enrollment. Advise patients with a surgically placed central line or subcutaneous port that removal of the port once enrolled on study would require holding study treatment for 4 weeks prior, and surgical removal of the central line or port would be recommended to be performed prior to cabozantinib initiation.
3. Patients must not have had a core or fine needle biopsy within 7 days of study enrollment.
4. Any surgical wounds or incisions must be healed, as determined by treating physician, prior to enrollment on study.
5. Bone marrow aspiration and/or biopsy are not considered surgical procedures for the purpose of this study.
13. Patients must be able to swallow tablets intact. Tablets cannot be cut or crushed.
14. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment. Post-menarchal females must be confirmed to not be pregnant at time of enrollment.
15. Patient or legal guardian must be capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
16. Patient must be able to start study treatment no later than 12 weeks after end of prior therapy, where 1 week = 7 days.
17. Patient must be enrolled on study within 14 days of qualifying radiographic imaging studies demonstrating best response as per Section 3.1.2.
18. Patient must be able to start study treatment no later than 7 days from study enrollment.
2. Patients previously with evaluable disease at start of most recent line of therapy, AND without measurable disease at that time are eligible based on "evaluable disease" definition alone only in Section 3.1.2.a.ii.
3. Patients previously with measurable AND evaluable disease at start of most recent line of therapy must meet BOTH "measurable disease" and "evaluable disease" definitions under Section 3.1.2.a.
3.2.2. Disease Strata. Patients need to meet any single definition of disease below:
1. Stratum A: Solid tumors with 1-year PFS ≤25% (target enrollment 36 patients)
1. Neuroblastoma BR1 at the end of frontline therapy with residual disease (less than complete response (CR), including MIBG-avid stable disease as per Section 3.1.2.a.ii,.or \>5% bone marrow involvement) but not progressive at time of enrollment
2. Neuroblastoma BR2 or later.
3. Osteosarcoma, BR2 or later
4. Ewing sarcoma, BR2 or later
5. Rhabdomyosarcoma, with positive surgical margins OR with primary extremity tumor with \>2 metastases at diagnosis, BR1 or later
6. Rhabdomyosarcoma, alveolar subtype or fusion-positive subtype, BR2 or later
7. Rhabdomyosarcoma, embryonal subtype, Group 4 at original diagnosis, BR2 or later
8. Desmoplastic small round blue cell tumor, BR2 or later
9. Any other soft tissue sarcoma, BR2 or later
10. Wilms tumor, diffuse anaplasia histology, any stage, BR2 or later
11. Wilms tumor, any histology with relapse within 12 months of diagnosis, who have received prior treatment with doxorubicin, and intraabdominal recurrence, BR2 or later
12. Wilms tumor, BR3 or later
13. Other solid tumor with 1-year PFS ≤ 20% can be discussed with study chair for eligibility
2. Stratum B: Metastatic Ewing sarcoma with metastases not undergoing complete metastatectomy, BR1 (target enrollment 20 patients)
3. Stratum C: Metastatic osteosarcoma after frontline therapy, BR1 (target enrollment 20 patients)
4. Stratum D: Metastatic fusion-positive rhabdomyosarcoma after frontline therapy, BR1 (target enrollment 10 patients)
1. Age: ≥ 18 months of age and \<40 years of age at time of study enrollment
2. Performance level: Patients must have a Lansky or Karnofsky performance status score of ≥ 50, corresponding to ECOG categories 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are upright in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. Patients should also have recovery to baseline or ≤ Grade 1 CTCAE v4.03 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy (see Section 3.2.3, criteria 4)
3. Patient Body Surface Area (BSA): Patients must be ≥0.35 m2 in BSA, using the Mosteller formula, BSA = (((Height in cm) \* (Weight in kg))/ 3600)½ within two weeks of study enrollment
4. Prior therapy: patients must have recovered from the acute toxic effects of prior therapy, with the following time specifications:
1. Myelosuppressive chemotherapy: Patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment on study (6 weeks if prior therapy included nitrosourea)
2. Other medicinal anti-cancer agents: Patients must not have received non-myelosuppressive anticancer agents, including any type of small molecule kinase inhibitor, within 14 days of enrollment on study
3. Biological anticancer therapy (including antibody therapy or cellular therapy): Patients must not have received biological anticancer therapy within 21 days of enrollment on study
4. Radiation therapy: Patients must not have received external beam radiation therapy to sites outside of the lungs within 2 weeks of study enrollment, external beam radiation therapy to sites within the lungs within 4 weeks of study enrollment, or I-131 MIBG therapy within 6 weeks of study enrollment. Subjects with clinically relevant ongoing complications from prior radiation therapy MUST be discussed with Study Chair or his proxy to determine suitability and safety of enrollment.
5. Myeloablative therapy: Patients must not have received myeloablative therapy within 2 months of study enrollment, must not have received a blood stem cell/marrow infusion within 3 weeks of study enrollment, and must have attained blood count recovery as per Section 3.2.3, criteria 5
5. Bone Marrow Function: Patients must have adequate bone marrow function at time of study enrollment, as defined as:
1. Absolute neutrophil count (ANC) ≥1000/mcL; patients cannot have received filgrastim, pegfilgrastim or equivalent biosimilar within 14 days of study enrollment
2. Platelet count ≥ 100,000/mcL; patients can receive no more than 15 mL/kg of platelet transfusions per week at time of enrollment to meet the parameters; patients can receive a TPO agonist (e.g., eltrombopag or romiplostim) at time of enrollment but must be on a stable dose for at least 14 days prior to enrollment
3. Hemoglobin ≥ 8.0 g/dL; patients can receive no more than 10 mL/kg of packed red blood cells (PRBCs)/week transfused at time of enrollment on therapy to meet the parameters; patients may receive erythropoietin or biosimilar equivalent but must have been on a stable dose and not require PRBC transfusions for at least 14 days prior to study enrollment
4. Patients with residual bone marrow metastases at end of most recent line of therapy must have stable disease or better at two bone marrow evaluations at least 4 weeks apart, with the second marrow assessment at least 4 weeks after end of most recent therapy. Stable disease is defined as \<2-fold change in marrow burden between the two timepoints and ≤20% marrow involvement. When bilateral bone marrow assessment is performed, average marrow involvement of the two sites will be used for eligibility.
6. Renal Function: Patient must meet criteria for both a. and b. below to have adequate renal function, within 2 weeks of study enrollment
1. Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2, as per institutional standard testing OR serum creatinine based on age/gender as listed in protocol:
2. Urine protein: ≤ 30 mg/dl in urinalysis (clean catch recommended), equivalent to ≤ 1+ on dipstick OR quantitative urine protein \< 1000 mg in a 24hr urine sample. NOTE: If the initial urinalysis shows \>30 mg/dL urine protein (or \> 1+ on dipstick), a 24-hour quantitative urine protein should be utilized, as described above, for eligibility consideration.
7. Hepatic function: Patient must meet ALL of the below criteria, within 14 days of study enrollment, to have adequate hepatic function:
1. Total bilirubin \< 2x institutional upper limit of normal (ULN) for age
2. ALT\<5x ULN
3. Serum albumin \>2.7 g/dL
8. Cardiovascular Function: Patients must have adequate cardiovascular function as defined as:
1. No significant arrhythmias, strokes, transient ischemic attacks, or myocardial infarction within 6 months of study enrollment
2. QTc ≤ 480 msec within 7 days of study enrollment (calculated using Bazett calculation or Fridericia calculation as per institutional standard of care; whichever calculation is used for eligibility must be used for all future QTc calculations).
A single ECG with QTc meeting the above criterion is adequate. However, if an initial ECG shows a QTc \>480 ms, obtain two additional ECGs with each ECG at least 30 minutes apart. Calculate each individual QTc by the same calculation method and average the values; the resulting average QTc will be used for eligibility.
3. Blood pressure ≤ 95th percentile for age, height, and gender for patients \<18 years of age (78), or BP ≤140/90 for patients ≥18 years of age. At time of enrollment, patients may be on one antihypertensive agent at a stable dose for at least 2 weeks prior to enrollment.
9. Pancreatic function: Patient must have adequate pancreatic function, as defined by a serum lipase \<2x ULN
10. Neurologic function: Patients with defined seizures who are on a stable anti- convulsant regimen using drugs that do not induce hepatic metabolizing enzymes for at least 4 weeks are eligible for enrollment Recommended Non-enzyme inducing anticonvulsants Clonazepam Diazepam Ethosuximide Ezogabine Gabapentin Lacosamide Lamotrigine Levetiracetam Lorazepam Perampanel Tiagabine Topiramate Valproic Acid Zonisamide Unacceptable Enzyme inducing anticonvulsants Carbamazepine Felbamate Phenobarbital Fosphenytoin Phenytoin Primidone Oxcarbazepine
11. Lung integrity: Patients must not have had any invasive pulmonary procedure (including bronchoalveolar lavage, lung biopsy, transbronchial biopsy, or thoracotomy) or pneumothorax within 4 weeks of enrollment on study.
12. Surgeries or trauma:
1. Patients must not have had any major surgical procedures, laparoscopic procedures, sepsis, shock, or physical trauma requiring hospitalization within 4 weeks of enrollment on study. The primary surgeon of any major surgical procedures must authorize antineoplastic treatment before enrollment on study.
2. Patients must not have had a central line or subcutaneous port placement, revision, or removal (excluding a peripherally inserted central catheter (PICC)) within 7 days of study enrollment. Advise patients with a surgically placed central line or subcutaneous port that removal of the port once enrolled on study would require holding study treatment for 4 weeks prior, and surgical removal of the central line or port would be recommended to be performed prior to cabozantinib initiation.
3. Patients must not have had a core or fine needle biopsy within 7 days of study enrollment.
4. Any surgical wounds or incisions must be healed, as determined by treating physician, prior to enrollment on study.
5. Bone marrow aspiration and/or biopsy are not considered surgical procedures for the purpose of this study.
13. Patients must be able to swallow tablets intact. Tablets cannot be cut or crushed.
14. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment. Post-menarchal females must be confirmed to not be pregnant at time of enrollment.
15. Patient or legal guardian must be capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
16. Patient must be able to start study treatment no later than 12 weeks after end of prior therapy, where 1 week = 7 days.
17. Patient must be enrolled on study within 14 days of qualifying radiographic imaging studies demonstrating best response as per Section 3.1.2.
18. Patient must be able to start study treatment no later than 7 days from study enrollment.
Minimum Eligible Age
18 Months
Maximum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Exelixis
INDUSTRY
Sponsor Role
collaborator
Nationwide Children's Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nilay Shah, MD
Role: PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Alabama/UAB
Birmingham, Alabama, United States
Site Status
RECRUITING
Children's Hospital of Colorado
Aurora, Colorado, United States
Site Status
RECRUITING
Children's National Medical Center
Washington D.C., District of Columbia, United States
Site Status
RECRUITING
Children's Hospital at Montefiore
The Bronx, New York, United States
Site Status
RECRUITING
Nationwide Children's Hospital
Columbus, Ohio, United States
Site Status
RECRUITING
Primary Children's Hospital
Salt Lake City, Utah, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CaboMain
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
NCT03811886
WITHDRAWN
PHASE1/PHASE2
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
NCT05608148
RECRUITING
PHASE1
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
NCT00001564
COMPLETED
PHASE2
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
NCT03618381
ACTIVE_NOT_RECRUITING
PHASE1
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
NCT00923351
COMPLETED
PHASE1/PHASE2
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888
ACTIVE_NOT_RECRUITING
PHASE2
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
NCT05634369
RECRUITING
PHASE1/PHASE2
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
NCT03441360
COMPLETED
PHASE2
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
NCT02258815
COMPLETED
PHASE2
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
NCT01697514
WITHDRAWN
PHASE1
Panitumumab in Children With Solid Tumors
NCT00658658
COMPLETED
PHASE1
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
NCT03015844
AVAILABLE
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066
RECRUITING
PHASE1/PHASE2
EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children
NCT00339118
UNKNOWN
PHASE4
Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children
NCT06341998
COMPLETED
PHASE2/PHASE3
Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia
NCT01678508
COMPLETED
Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma
NCT00003793
COMPLETED
Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma
NCT00003801
COMPLETED
NA
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
NCT02478502
TERMINATED
PHASE2
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
NCT01585649
COMPLETED
PHASE1
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas
NCT01216839
UNKNOWN
PHASE2
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
NCT03245450
COMPLETED
PHASE1/PHASE2
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
NCT00704054
COMPLETED
PHASE1
Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma
NCT00055939
COMPLETED
PHASE2
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272
RECRUITING
PHASE1/PHASE2